(Cincinnati, OH; December 6, 2011) – Camargo Pharmaceutical Services, an end-to-end drug development service provider specializing in the 505(b)(2) process, has set a course for the future growth of the company by appointing Mark Bolin as vice president of corporate development.
In his new role, Bolin will utilize over 25 years of pharmaceutical and health care industry experience to advance the company through strategic financial and technical partnerships to meet the needs of the marketplace. An increasing number of new drug approvals are using the 505(b)(2) pathway, which requires full safety and effectiveness reports but allows the use of other companies’ study results, thereby taking a fraction of the time and cost required by traditional paths.
“Camargo’s recent expansion with the opening of our Durham, N.C., office and the potential to open additional offices will extend our company’s reach to clients around the globe, while making our extensive regulatory expertise available to meet the increasing demand in formulation, preclinical and clinical services,” stated Ken Phelps, president and CEO. “Mark will serve as the business arm and his substantial experience setting companies up for growth via financial and operational management will be an asset to Camargo.”
Prior to his employment at Camargo, Bolin served as a founding member and chief financial officer of Ricetta Rx Holdings LLC. While there, he helped secure a long-term care pharmacy business through acquisition and organic growth. Bolin was responsible for identifying and targeting acquisition candidates, negotiating acquisition term sheets and asset purchase agreements and managing the financial operations of the company. The company was sold in a series of transactions in 2008 and 2011 to both public and private equity backed entities.
Bolin is a certified public accountant and is a graduate of the University of Kentucky.
About Camargo Pharmaceutical Services
Camargo Pharmaceutical Services is an end-to-end drug development service provider specializing in the 505(b)(2) approval pathway. Camargo works with companies to develop comprehensive programs, managing every facet of the plan from formulating and testing the drug product, to conducting clinical studies and FDA application submissions. Connect with Camargo on LinkedIn, the President’s blog or visit www.camargopharma.com for more information.
